Danish Marine and Shipping Stock News

NKT (CPSE:NKT) has secured its largest single cable contract, a firm agreement worth more than €2.2b for the Eastern Green Link 3 HVDC project in the UK. This deal expands the company’s high voltage order backlog. See our latest analysis for NKT. NKT’s EGL3 contract and recent decision to refinance its subordinated capital securities come against a backdrop of firm share price momentum, with a 1 day share price return of 3.3%, a 7 day share price return of 8.4%, and a 1 year total shareholder...

Share buy-back puts Alm. Brand (CPSE:ALMB) in focus Alm. Brand (CPSE:ALMB) has drawn fresh investor attention after announcing a share buy-back program of up to DKK 835.2 million, with the company now holding 3.44% of its own shares. See our latest analysis for Alm. Brand. At a share price of DKK16.34, Alm. Brand has seen a 1-day share price return of 1.24% and a 7-day share price return of 2.57%, although the 30-day and year-to-date share price returns of 4.28% and 12.15% declines suggest...

If you are wondering whether Danske Bank shares still offer value after a strong run, this article walks through what the current price might be implying about the company. The stock last closed at DKK 325.30, with returns of 2.7% over 7 days, a 4.4% decline over 30 days, 1.8% year to date and 48.2% over 1 year, while the 3 year and 5 year returns stand at 169.7% and 239.3% respectively. Recent headlines around Danske Bank have focused on its position among Nordic lenders and how investors...

How Novozymes Shares Have Been Performing Novozymes (CPSE:NSIS B) has been under pressure recently, with the stock showing a 2.3% decline over the past day and deeper pullbacks over the past week, month, and past 3 months. Over the past year, Novozymes has delivered a total return of 9.6%. The year to date move reflects a 10.5% decline. Looking at longer periods, the 3 year total return stands at 11.9%, and the 5 year total return shows a 4.0% decline. See our latest analysis for...

CEO change puts fresh focus on Coloplast shares Coloplast (CPSE:COLO B) is back in focus after the board named Gavin Wood as President and CEO, effective May 1, 2026, following a period under interim chief Lars Rasmussen. See our latest analysis for Coloplast. The CEO announcement comes after a weaker run for the shares, with a 7 day share price return of 7.04% and a 90 day share price return of 20.51%. This has contributed to a 1 year total shareholder return of 37.52% and a 5 year total...

A.P. Møller - Mærsk recently suspended key container services linking the Middle East with Europe and Asia, along with Gulf shuttle operations, and altered its ME1 rotation to bypass Jebel Ali as it responds to heightened security risks in the region. This shift reroutes cargo away from a major Middle Eastern hub, potentially reshaping how global shippers manage transit times, capacity, and supply chain resilience across these trade lanes. We’ll now examine how this temporary suspension of...

Aktieselskabet Schouw (CPSE:SCHO) just reported full year 2025 results, pairing lower net income with a higher proposed dividend and strong cash flow. This combination gives you several angles to assess the stock. See our latest analysis for Aktieselskabet Schouw. These results land after a weak run in the share price, with a 7 day share price return of 7.60% and a 30 day share price return of 10.40%. However, the 1 year total shareholder return of 4.31% and 3 year total shareholder return of...

Zealand Pharma (CPSE:ZEAL) is under close watch after Phase 2 topline data for obesity drug candidate petrelintide triggered a sharp share price drop, despite meeting the trial’s primary weight loss and safety goals. See our latest analysis for Zealand Pharma. The sharp 1 day share price return of 36.4% and 7 day share price return of 36.1% have reversed much of Zealand Pharma’s earlier gains. However, the 3 year total shareholder return of 4.9% and 5 year total shareholder return of 23.7%...

Earnings jump puts UIE (CPSE:UIE) in focus UIE (CPSE:UIE) is back on the radar after reporting full year 2025 earnings, with sales of US$587.28 million and net income of US$139.92 million, alongside basic EPS of US$4.48 from continuing operations. See our latest analysis for UIE. The earnings release comes after a mixed period for the shares, with a 1-day share price return of 0.98% and 7-day share price return of 0.84%. This is set against a 30-day share price return of 4.50% and year to...

If you are wondering whether Aktieselskabet Schouw is attractively priced right now, the starting point is to separate what the share price is doing from what the underlying value might suggest. The stock last closed at DKK 634.0, with returns of a 6.4% decline over 7 days, a 6.1% decline over 30 days, a 4.5% decline year to date, and a 5.8% gain over 1 year, a 20.5% gain over 3 years, and a 10.1% gain over 5 years. Taken together, this gives you a mixed picture of recent sentiment over...

Zealand Pharma reported positive Phase 2 topline results for petrelintide, its obesity drug candidate, with clinically meaningful weight loss and strong tolerability. The trial met its primary weight reduction endpoint and showed a favorable safety profile, according to the company. The news has arrived as investors reassess Zealand Pharma’s position in the obesity drug space and its collaboration with Roche. For holders of CPSE:ZEAL, the latest petrelintide data lands after a sharp reset...

For investors wondering whether Bavarian Nordic is attractively priced at its current level or whether the recent share price leaves less room for upside, this article walks through what the numbers indicate about value. The stock last closed at kr188.25, with returns of a 4.4% decline over 7 days, a 1.7% decline over 30 days, a 2.4% decline year to date, a 12.1% gain over 1 year, a 9.6% decline over 3 years, and a 14.0% decline over 5 years. Recent headlines around Bavarian Nordic have kept...

Carlsberg has confirmed it is considering an IPO of its India business. The company publicly acknowledged ongoing speculation around the India listing plans. The potential IPO would give investors a direct way to gain exposure to Carlsberg’s India operations. For investors watching CPSE:CARL B, the confirmation around a possible India IPO comes at a time when the shares trade at DKK969.2. The stock is up 13.6% over the past 30 days and 17.4% year to date, with a 12.3% return over 5 years...

Per Aarsleff Holding A/S reported first-quarter 2025/26 results with sales rising to DKK 6,180 million and net income reaching DKK 187 million, modestly above the prior year. Separately, PURIS announced that PAA will become a part owner in a new LiquiForce partnership, extending Per Aarsleff’s technical footprint in Canadian infrastructure rehabilitation through shared LED-light curing and lateral renewal solutions. We’ll now examine how Per Aarsleff’s higher quarterly earnings and...

TORM plc recently reported full-year 2025 results showing sales of US$1.34 billion and net income of US$285.3 million, alongside new 2026 TCE earnings guidance of US$850 million to US$1.25 billion. The board also approved a Q4 2025 interim dividend of US$0.70 per share, highlighting management’s willingness to return substantial cash to shareholders even as earnings moderated year over year. With this combination of firm 2026 TCE guidance and a sizeable Q4 dividend, we’ll now examine how the...

Société Générale has cut its shareholding in ISS A/S (CPSE:ISS) to below 5%, triggering a regulatory disclosure of a change in major shareholder status. The move marks a shift in ISS’s ownership structure that investors may watch for potential implications for governance and market sentiment. ISS, listed as CPSE:ISS, is a global facility services provider. Changes in its major shareholders tend to catch the eye of investors who follow long contract cycles and customer retention trends. The...

ALK-Abelló A/S recently reported full-year 2025 results showing sales of DKK 6,312 million and net income of DKK 1,197 million, confirmed an 11–15% local-currency revenue growth outlook for 2026, announced an annual dividend of DKK 1.60 per share, and disclosed that EVP of R&D Henriette Mersebach will step down in February 2026 while supporting the transition. The combination of stronger earnings, growth guidance under the Allergy+ strategy, and a planned change in R&D leadership highlights...

On 20 February 2026, RWE announced a firm order with Vestas for 92 V236-15.0 MW turbines for the 1,380 MW Vanguard West offshore wind project in the UK, with Vestas supplying, delivering, commissioning, and servicing the turbines under a comprehensive multi-year agreement. This large UK offshore order highlights how Vestas’ V236 platform and service capabilities are being applied at utility scale across a major European project. We’ll now examine how securing this large Vanguard West...

In February 2026, Novo Nordisk reported phase 3 REDEFINE 4 data showing its CagriSema obesity injection delivered less weight loss than Eli Lilly’s Zepbound, while also outlining future high‑dose trials and ongoing REDEFINE and REIMAGINE programs across obesity and type 2 diabetes. At the same time, Novo Nordisk moved to defend its obesity and diabetes franchise with deeper Wegovy price cuts from 2027, an expanded Wegovy 7.2 mg dose in the EU, and new partnerships and pipeline assets,...

Why Demant (CPSE:DEMANT) Is Back in Focus for Investors Demant (CPSE:DEMANT) is drawing fresh attention after gaining market share in the US Veterans Affairs hearing aid channel, while at the same time expanding cost saving layoffs at its Danish operations. See our latest analysis for Demant. The recent gain in US Veterans Affairs market share and the expanded cost-saving program comes after a mixed price pattern, with an 8.07% 7-day share price return, a 30-day share price return of 11.11%,...

DSV (CPSE:DSV) is back in focus after signing a two year Ship Green framework agreement with Hapag Lloyd. The agreement targets 18,000 tonnes of CO₂e emission reductions through sustainable marine fuels in ocean freight. See our latest analysis for DSV. The Ship Green deal comes as DSV’s 90 day share price return of 10.88% contrasts with a softer 30 day share price return of 6.90% and a 12 month total shareholder return of 12.99%. This suggests earlier momentum has cooled recently while...

Vestas Wind Systems (CPSE:VWS) has secured a major turbine order for RWE's 1,380 MW Vanguard West offshore wind project in the United Kingdom. The project adds a large UK offshore scheme to Vestas' order book and relates to a key part of the region's offshore wind pipeline. For you as an investor watching CPSE:VWS, this contract is closely linked to Vestas' core business of supplying wind turbines and related services. Offshore wind has been an area of policy focus in the UK, and government...

FLSmidth (CPSE:FLS) has completed its shift into a pure-play mining technology provider following the divestment of its cement business. The company has appointed Toni Laaksonen as CEO and announced a reshaped Board, including a new proposed Chair and several departures. New executives have been named to lead key mining business lines, signaling an organizational reset around the mining portfolio. FLSmidth now trades as a focused mining technology and services company, with its...

Methanex, Ørsted and Exolum have launched the U.K.’s first commercially ready biomethanol storage and marine bunkering service at the Port of Immingham, providing low‑carbon fuel for shipping and supporting Ørsted’s North Sea offshore wind maintenance vessels. The project shows how existing fuel infrastructure can be re‑tooled for green fuels, offering a practical pathway to cut domestic shipping emissions that currently exceed those from buses, trains and domestic aviation combined in the...